Litcius/Paper detail

Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update

Céline Habre, A. Dabadie, Anderson Loundou, Jean-Bruno Banos, C. Desvignes, H. Pico, A. Aschero, N. Colavolpe, Charlotte Seiler, Corinne Bouvier, Émilie Peltier, Jean‐Claude Gentet, C. Baunin, Pascal Auquier, Philippe Petit

2021Pediatric Radiology17 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Diffusion-weighted imaging (DWI) has been described to correlate with tumoural necrosis in response to preoperative chemotherapy for osteosarcoma. OBJECTIVE: To assess the accuracy of DWI in evaluating the response to neoadjuvant chemotherapy at the mid-course treatment of long-bone osteosarcoma and in predicting survival. MATERIALS AND METHODS: We conducted a prospective single-centre study over a continuous period of 11 years. Consecutive patients younger than 20 years treated with a neoadjuvant regimen for peripheral conventional osteosarcoma were eligible for inclusion. Magnetic resonance imaging (MRI) with DWI was performed at diagnosis, and mid- and end-course chemotherapy with mean apparent diffusion coefficients (ADC) calculated at each time point. A percentage less than or equal to 10% of the viable residual tissue at the histological analysis of the surgical specimen was defined as a good responder to chemotherapy. Survival comparisons were calculated using the Kaplan-Meier method. Uni- and multivariate analyses with ADC change were performed by Cox modelling. This is an expansion and update of our previous work. RESULTS: Twenty-six patients between the ages of 4.8 and 19.6 years were included, of whom 14 were good responders. At mid-course chemotherapy, good responders had significantly higher mean ADC values (P=0.046) and a higher increase in ADC (P=0.015) than poor responders. The ADC change from diagnosis to mid-course MRI did not appear to be a prognosticator of survival and did not impact survival rates of both groups. CONCLUSION: DWI at mid-course preoperative chemotherapy for osteosarcoma should be considered to evaluate the degree of histological necrosis and to predict survival. The anticipation of a response to neoadjuvant treatment by DWI may have potential implications on preoperative management.

Topics & Concepts

MedicineOsteosarcomaEffective diffusion coefficientChemotherapyNeuroradiologyDiffusion MRIMagnetic resonance imagingRadiologyRegimenChemotherapy regimenNuclear medicineSurgeryPathologyNeurologyPsychiatrySarcoma Diagnosis and TreatmentMRI in cancer diagnosisBone and Joint Diseases